



BioLineRx to Report First Quarter 2013 Results on May 7, 2013

April 30, 2013

Management to Hold Conference Call at 10:00 A.M. EST

JERUSALEM--(BUSINESS WIRE)--Apr. 30, 2013-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the quarter ended March 31, 2013 on Tuesday, May 7, 2013, before the U.S. markets open.

The Company will host a conference call on Tuesday, May 7 at 10:00 a.m. EDT, featuring remarks by Kinneret Savitsky, Ph.D., CEO of BioLineRx, and Philip Serlin, Chief Financial and Operating Officer of BioLineRx. The conference call will be available via webcast and can be accessed through the Investor Relations section of BioLineRx's website at www.bioglinerx.com or at www.kcsa.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. To dial into the conference call, please dial 1-888-668-9141 from the U.S. or +972-3-918-0609 internationally.

A replay of the conference call will be available approximately two hours after completion of the live conference call at www.bioglinerx.com or www.kcsa.com. A dial-in replay of the call will be available until May 10, 2013; please dial 1-888-295-2634 from the U.S. or +972-3-925-5921 internationally.

About BioLineRx

BioLineRx is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx's current portfolio consists of seven clinical stage candidates: BL-1040, for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc., is currently undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions has completed a Phase I/II study; BL-7040 for treating inflammatory bowel disease (IBD) has completed a Phase IIa trial; BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers will shortly commence a Phase II study; BL-1021 for neuropathic pain is in Phase I development; BL-8020 for hepatitis C (HCV) has commenced a Phase I/II study; and BL-1020 for schizophrenia. In addition, BioLineRx has five products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx's business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government's Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase III) and commercialization. For more information on BioLineRx, please visit www.bioglinerx.com, the content of which does not form a part of this press release.

Source: BioLineRx Ltd.

KCSA Strategic Communications
Garth Russell, 1 212-896-1250
grussell@kcsa.com

or

Todd Fromer, 1 212-896-1215
tfromer@kcsa.com

or

Tsipi Haitovsky, Public Relations
+972-52-598-9892
tsjih@netvision.net.il